This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Astra Zeneca U.k. Limited. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Andrew Dippel: Innovator in Antibody Research
Introduction
Andrew Dippel is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target the spike protein of SARS-CoV-2. His work is crucial in the ongoing fight against COVID-19.
Latest Patents
Andrew Dippel holds a patent for "Antibodies That Bind the Spike Protein of SARS-CoV-2." This innovation is vital for therapeutic and diagnostic applications related to the virus.
Career Highlights
Dippel is currently employed at AstraZeneca U.K. Limited, where he continues to advance his research in antibody development. His expertise in this area has positioned him as a key player in the biotechnology sector.
Collaborations
Andrew has collaborated with talented coworkers such as Taylor Cohen and Saravan Rajan, contributing to a dynamic research environment that fosters innovation.
Conclusion
Andrew Dippel's work in antibody research exemplifies the impact of innovation in addressing global health challenges. His contributions are paving the way for advancements in therapeutic solutions for COVID-19.